---
url: "https://www.lek.com/leadership/max-cambras"
title: "Max Cambras | L.E.K. Consulting"
---

[Skip to main content](https://www.lek.com/leadership/max-cambras#main-content)

[![L.E.K.](https://www.lek.com/themes/lek/images/new-logo.svg)](https://www.lek.com/ "L.E.K.")

Search

- English
- List additional actions
- [Português](https://www.lek.com/pt-br/lek-brazil)
- [简体中文](https://www.lek.com/zh-hant/lek-china)
- [Deutsch](https://www.lek.com/de/lek-germany)
- [日本語](https://www.lek.com/ja/lek-japan)

# Max Cambras

Max Cambras is a Managing Director and Partner in L.E.K.’s Life Sciences practice and is based in New York. He has over 17 years’ experience working with biopharmaceutical companies on commercialization strategy, innovation planning and management, drug delivery and digital health and patient engagement.

Prior to joining L.E.K., Max was a senior manager in the marketing analytics group at Purdue Pharma. He received a Bachelor of Arts from the University of Chicago and a Master of Arts from the University of Iowa.

### Education

**Undergraduate:** Bachelor of Arts, University of Chicago

**Graduate:** Master of Arts, University of Iowa

![Max Cambras headshot](https://www.lek.com/sites/default/files/profile-images/LEK_Leader_Profile_Max_Cambras_0.jpg)

### Max's Expertise

#### Industries

[Life Sciences Consulting](https://www.lek.com/industries/life-sciences-pharma)

#### Capabilities

[Digital](https://www.lek.com/capabilities/digital)

[Strategy](https://www.lek.com/capabilities/strategy)

Read more

### Related Insights

[Executive Insights\\
\\
\\
**Life Sciences & Pharma****Future Outlook for the AOM Market**\\
\\
January 9, 2025](https://www.lek.com/insights/hea/us/ei/future-outlook-aom-market)

[Case Study\\
\\
\\
**Data & Analytics****Predicting Pandemics: Models Deliver 90% Forecast Accuracy for Biopharma Giant**\\
\\
June 17, 2024](https://www.lek.com/insights/all/us/cs/predicting-pandemics-models-deliver-90-forecast-accuracy-biopharma-giant)

[Podcast\\
\\
\\
**Life Sciences & Pharma****Scope 3 Emissions: A Strategic Imperative for Pharma Companies**\\
\\
May 8, 2024](https://www.lek.com/insights/hea/global/po/scope-3-emissions-strategic-imperative-pharma-companies)

[Case Study\\
\\
\\
**Life Sciences & Pharma****Cost and Reimbursement Assessment for a Biopharmaceutical Company**\\
\\
May 7, 2024\\
\\
A large biopharmaceutical company developing chimeric antigen receptor T-cell (CAR-T) therapies](https://www.lek.com/insights/hea/global/cs/cost-and-reimbursement-assessment-biopharmaceutical-company)

[Special Report\\
\\
\\
**Biotech and Pharmaceuticals****Scope 3 Emissions: A Strategic Imperative for Pharma Companies**\\
\\
March 19, 2024](https://www.lek.com/insights/hea/global/sr/scope-3-emissions-strategic-imperative-pharma-companies)

[Executive Insights\\
\\
\\
**Life Sciences & Pharma****The Inflation Reduction Act: Implications for Drug Delivery Innovation**\\
\\
January 3, 2024](https://www.lek.com/insights/hea/us/ei/inflation-reduction-act-implications-drug-delivery-innovation)

- [Load more](https://www.lek.com/leadership/max-cambras?page=1 "Load more items")

First name

Last name

Email

Phone number

My locationUnited StatesCanadaAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia and HerzegovinaBotswanaBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzech RepublicCôte d’IvoireDemocratic Republic of the CongoDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHondurasHong Kong S.A.R., ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao S.A.R., ChinaMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian TerritoryPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSaint BarthélemySaint HelenaSaint Kitts and NevisSaint LuciaSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth KoreaSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVaticanVenezuelaViet NamWallis and FutunaWestern SaharaYemenZambiaZimbabwe

Reason for contactingBusiness - I'm exploring hiring L.E.K.Press - I'm a media representative seeking an L.E.K. expert perspectiveCareer - I'm exploring working at L.E.K.Events - I'm looking to invite L.E.K. to participate in an upcoming eventOther

Company

Message

Comments

By clicking “Contact me” I acknowledge and agree to the L.E.K. Consulting [Privacy Notice](https://www.lek.com/lek-consulting-privacy-policy).

×